2,5,7-tris(trifluoromethyl)-4-quinolinol | 1141428-39-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2,5,7-tris(trifluoromethyl)-4-quinolinol
• 英文别名: 2,5,7-Tris(trifluoromethyl)-4-quinolinol；2,5,7-tris(trifluoromethyl)-1H-quinolin-4-one
• CAS: 1141428-39-8
• 化学式: C₁₂H₄F₉NO
• 分子量: 349.155
• InChiKey: BJMNTNLQCUGMHX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  23
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  2,5,7-tris(trifluoromethyl)-4-quinolinol 、 3-溴丙炔 在 potassium carbonate 、 potassium iodide 作用下， 以 丙酮 为溶剂， 反应 1.0h， 以74%的产率得到2,5,7-tris(trifluoromethyl)-4-propargyloxyquinoline
  参考文献：
  名称：

  [EN] ANTIBIOTIC COMPOSITIONS
  [FR] COMPOSITIONS ANTIBIOTIQUES

  摘要：

  本公开涉及具有抗微生物活性的化合物，包括这些化合物与β-内酰胺类抗生素结合的组合物，以及使用这些化合物和组合物的方法。

  公开号：

  WO2017136642A1
• 作为产物：
  描述：

  三氟乙酰乙酸乙酯 、 间二(三氟甲基)苯胺 在 PPA 作用下， 生成 2,5,7-tris(trifluoromethyl)-4-quinolinol
  参考文献：
  名称：

  Structure−Activity Relationships for a Series of Quinoline-Based Compounds Active against Replicating and Nonreplicating Mycobacterium tuberculosis

  摘要：

  Tuberculosis (TB) remains as a global pandemic that is aggravated by a lack of health care, the spread of HIV, and the emergence of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) strains. New anti-TB drugs are urgently required to shorten the long 6-12 month treatment regimen and to battle drug-resistant Mtb strains. We have identified several potent quinoline-based anti-TB compounds, bearing an isoxazole containing side-chain. The most potent compounds, 7g and 13, exhibited submicromolar activity against the replicating bacteria (R-TB), with minimum inhibitory concentrations (MICs) of 0.77 and 0.95 mu M, respectively. In general, these compounds also had micromolar activity against the nonreplicating persistent bacteria (NRP-TB) and did not show toxicity on Vero cells up to 128 mu M concentration. Compounds 7g and 13 were shown to retain their anti-TB activity against rifampin, isoniazid, and streptomycin resistant Mtb strains. The results suggest that quinoline-isoxazole-based anti-TB compounds are promising leads for new TB drug development.

  DOI：

  10.1021/jm900003c

文献信息

• [EN] ANTIBIOTIC COMPOSITIONS<br/>[FR] COMPOSITIONS ANTIBIOTIQUES
  申请人：DARTMOUTH COLLEGE

  公开号：WO2017136642A1

  公开（公告）日：2017-08-10

  The present disclosure relates to compounds having antimicrobial activity, compositions comprising said compounds in combination with β-lactam antibiotics, and methods of using the compounds and compositions.

  本公开涉及具有抗微生物活性的化合物，包括这些化合物与β-内酰胺类抗生素结合的组合物，以及使用这些化合物和组合物的方法。
• Structure−Activity Relationships for a Series of Quinoline-Based Compounds Active against Replicating and Nonreplicating <i>Mycobacterium tuberculosis</i>
  作者：Annamaria Lilienkampf、Jialin Mao、Baojie Wan、Yuehong Wang、Scott G. Franzblau、Alan P. Kozikowski

  DOI：10.1021/jm900003c

  日期：2009.4.9

  Tuberculosis (TB) remains as a global pandemic that is aggravated by a lack of health care, the spread of HIV, and the emergence of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) strains. New anti-TB drugs are urgently required to shorten the long 6-12 month treatment regimen and to battle drug-resistant Mtb strains. We have identified several potent quinoline-based anti-TB compounds, bearing an isoxazole containing side-chain. The most potent compounds, 7g and 13, exhibited submicromolar activity against the replicating bacteria (R-TB), with minimum inhibitory concentrations (MICs) of 0.77 and 0.95 mu M, respectively. In general, these compounds also had micromolar activity against the nonreplicating persistent bacteria (NRP-TB) and did not show toxicity on Vero cells up to 128 mu M concentration. Compounds 7g and 13 were shown to retain their anti-TB activity against rifampin, isoniazid, and streptomycin resistant Mtb strains. The results suggest that quinoline-isoxazole-based anti-TB compounds are promising leads for new TB drug development.